NCT00976950已完成不适用
A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Tipranavir (Aptivus®) Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 42
- 试验地点
- 20
- 主要终点
- Number of Patients Reporting Adverse Events (AE)
研究概览
简要总结
The aim of this trial is to evaluate the safety and virological and immunological efficacy of Aptivus in treatment-experienced patients with advanced HIV-1 infection who had developed resistance to more than one protease inhibitor.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Patients with HIV-1 infection
干预措施: Tipranavir (Drug)
Patients with HIV-1 infection
干预措施: ritonavir (Drug)
结局指标
主要结局
Number of Patients Reporting Adverse Events (AE)
时间窗: 48 weeks
Any type of adverse events
次要结局
- Virologic Response(48 weeks)
- Change in CD4+ Cell Count From Baseline at Week 48(48 weeks)
研究者
研究点 (20)
Loading locations...
相似试验
已完成
4 期
Efficacy Trial of a Commercial EV71 VaccineHand, Foot and Mouth DiseaseNCT03903926Sinovac Biotech Co., Ltd15,500
已完成
不适用
Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)DiabetesDiabetes Mellitus, Type 2NCT02321878Novo Nordisk A/S1,092
已完成
不适用
Effectiveness and Safety in Patients With Crohn´s Disease in Clinical RoutineCrohn's DiseaseNCT01083680AbbVie (prior sponsor, Abbott)4,107
暂停
不适用
Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I DisorderAgitation,PsychomotorNCT03513549Alexza Pharmaceuticals, Inc.10,000
已完成
不适用
A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19SARS-CoV-2 InfectionNCT05263908Pfizer3,346